Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?
TheFly reported on June 12 that Guggenheim analyst Brad Canino reduced the price target for SNDX to $31 from $34 while maintaining a Buy rating on the shares.







